CREO Creo Medical Group PLC
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develops CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. It also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device. In addition, the company provides injection needles, hemostatic clips, snares, and forceps, as well as other products for gastroenterology, pulmonology, and urology. Further, it offers products for diagnostic, therapeutic, and hygiene purposes. Creo Medical Group PLC was founded in 2003 and is headquartered in Chepstow, the United Kingdom.…
Industry Peers
Medical DevicesKey Statistics
About Creo Medical Group (LON: CREO)
›
Creo Medical Group (LON: CREO) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 104 employees.
The shares were at 9.200 GBp on 20 November 2026, down 14.4% over 52 weeks.
Its market capitalisation is 41.32M GBP.
Creo Medical Group reports return on equity of 10.6%, an operating margin of -250.0% and revenue up 45.5% year over year.
It holds more cash than debt, a net cash position of 3.50M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.